Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
The post Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial appeared first on Business News.
Stellantis CEO Antonio Filosa on Wednesday reconfirmed the company's 2026 guidance and its plans to …
Tata Trusts senior trustee Venu Srinivasan has sought an investigation into why the philanthropic arm …
The Hampshire group says it has seen a rise in demand and it needs more …
